The new results show 46 percent reduction in C-reactive protein (CRP), a marker for inflammation, in patients treated with 40 mg of rosuvastatin and 10 mg ezetimibe.

“Inflammation can lead to serious complications such as heart attack and stroke, and high levels of CRP can predict these risks years before they actually occur,” said Dr. Christie Ballantyne, cardiologist at the Methodist DeBakey Heart Center and principle investigator for the study. “Physicians have long relied on blood cholesterol as a key indicator of cardiovascular risk, but recent research suggests that high risk patients who achieved a low CRP level combined with a low LDL-c level had the fewest cardiovascular events.”

The study looked at data from 465 patients in five different countries. A combination treatment regimen of 40 mg of rosuvastatin and 10 mg of ezetimibe demonstrated a 46 percent reduction in levels of CRP in high-risk patients. In six weeks, the combination regimen also helped 58 percent of patients achieve dual goals1 of lowering CRP and LDL-c (bad cholesterol).

Significantly more patients (58% vs. 24%) achieved an LDL-C <100 mg/dL or <70 mg/dL (depending on risk category) and CRP <2 mg/L at six weeks with rosuvastatin 40mg and ezetimibe 10mg compared with rosuvastatin 40 mg monotherapy. Rosuvastatin and ezetimibe reduced CRP levels by 46% compared with 29% with rosuvastatin monotherapy. Rosuvastatin and ezetimibe also reduced mean LDL-C by an unprecedented 70%. Significantly (p<0.001) more patients achieved their NCEP ATP III LDL-C goal of <100 mg/dL (94% vs 79%) at six weeks with rosuvastatin and ezetimibe compared with rosuvastatin monotherapy. Both rosuvastatin monotherapy and rosuvastatin combined with ezetimibe produced similar increases in HDL-C (“good” cholesterol) (8.5% vs. 10.8%). Rosuvastatin and ezetimibe were both well tolerated.; Source: Methodist Hospital, Houston